SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
Allogeneic, Autologous, BCMA, CAR-T, CD19, Dual/triple agonist

Arcellx’s CART-ddBCMA Program to Be Expanded; Precision to Provide Clinical Updates on Azer-cel and PBCAR19B Programs in May 2023; Arcellx’s and Precision’s Q1 2023 Results Summary

Here is a brief preview of this blast: On Monday, May 8, Arcellx released its Q1 2023 results (press release) highlighting the progress made in the clinical development of its lead asset CART-ddBCMA (autologous BCMA CAR-T) for ≥4L MM. A day later, Precision reported a business update (press release) confirming that clinical updates for its allogeneic CD19 CAR-Ts (azer-cel and PBCAR19B) in NHL patients are still anticipated in May 2023. Below, Celltelligence provides insights on the potential expansion of the CART-ddBCMA’s iMMagine program with a future iMMagine-3 trial while commenting on the expected clinical updates of Precision’s cell therapy assets.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.